Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Academic Article Article uri icon

Overview

MeSH

  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Clarithromycin
  • Dexamethasone
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Survival Rate
  • Thalidomide
  • Thrombocytopenia

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Multiple Myeloma

abstract

  • The objective of this case-matched study was to compare the efficacy and toxicity of the addition of clarithromycin (Biaxin) to lenalidomide/low-dose dexamethasone (BiRd) vs. lenalidomide/low-dose dexamethasone (Rd) for newly diagnosed myeloma. Data from 72 patients treated at the New York Presbyterian Hospital-Cornell Medical Center were retrospectively compared with an equal number of matched pair mates selected among patients seen at the Mayo Clinic who received Rd. Case matching was blinded and was performed according to age, gender, and transplant status. On intention-to-treat analysis, complete response (45.8% vs. 13.9%, P < 0.001) and very-good-partial-response or better (73.6% vs. 33.3%, P < 0.001) were significantly higher with BiRd. Time-to-progression (median 48.3 vs. 27.5 months, P = 0.071), and progression-free survival (median 48.3 vs. 27.5 months, P = 0.044) were higher with BiRd. There was a trend toward better OS with BiRd (3-year OS: 89.7% vs. 73.0%, P = 0.170). Main grade 3-4 toxicities of BiRd were hematological, in particular thrombocytopenia (23.6% vs. 8.3%, P = 0.012). Infections (16.7% vs. 9.7%, P = 0.218) and dermatological toxicity (12.5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results. © 2010 Wiley-Liss, Inc.

publication date

  • September 2010

has subject area

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • Case-Control Studies
  • Clarithromycin
  • Dexamethasone
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Survival Rate
  • Thalidomide
  • Thrombocytopenia

Research

keywords

  • Clinical Trial
  • Comparative Study
  • Journal Article
  • Multicenter Study

Identity

Language

  • eng

PubMed Central ID

  • PMC3956597

Digital Object Identifier (DOI)

  • 10.1002/ajh.21777

PubMed ID

  • 20645430

Additional Document Info

start page

  • 664

end page

  • 669

volume

  • 85

number

  • 9